Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)
Makaleler > Tam Makale · 2013
Yazarlar: Fikri Icli, Kadri Altundag, Hakan Akbulut, SEMRA PAYDAŞ, Gul Basaran, Pinar Saip, Gamze G. Dogu, Yesim Erlap, RÜÇHAN USLU, Alper Sevinc, Handan Onur, Nil M. Mandel, Canfeza Sezgin, Mustafa Altinbas, Nilufer Guler, Abdurrahman Isikdogan, Erhan GÖKMEN, Kazim Uygun, Zeki Ustuner, Arzu Yaren, Binnaz Demirkan, Ugur Coskun, Alper Ata, Metin Ozkan, Ali Arican
Breast Cancer, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2013, cilt 22, ss 480-485
DOI: 10.1007/s12282-013-0506-y
Özet
Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.